We calculated the negative predictive value of a negative or discordant rapid test. Because patients with two rapid positive tests were considered HIV-infected, without verification using an independent serological test, we were unable to

calculate the specificity of the rapid HIV tests in this study. We therefore calculated the negative predictive value assuming 100% specificity (as reported by some of the individual rapid test kit manufacturers) and then performed a sensitivity analysis incorporating published specificity results (90.4%) from a Ugandan study of rapid test diagnostic accuracy [22]. During the 9-month study period, 1005 patients enrolled in the study with rapid HIV test negative Trametinib price or discordant results from the out-patient department. Eleven patients either did not complete the venipuncture or had an inadequate specimen. The remaining 994 patients had ERK inhibitor manufacturer qualitative HIV RNA screen data available and were considered for the analysis (Fig. 1 and Table 1). Fifty-eight per cent of the enrolled cohort were female; the median age was 36 years. The results of background HIV testing during the study period were: 1294 patients had reactive rapid HIV tests (53% female; median age 34 years); 1429 subjects overall had negative rapid HIV tests (56% female; median age 38 years). Thirty-four

patients (22 with rapid test negative and 12 with rapid test discordant) had a positive qualitative HIV RNA screen. Two patients had negative rapid HIV tests with a positive qualitative RNA screen, but had undetectable quantitative HIV RNA and negative serum antibody tests; these patients were considered HIV negative. One subject had a positive qualitative HIV RNA screen but had no WB or HIV RNA available (Fig. 1). Of the 994 patients, 11 had acute

HIV infection, for a prevalence of 1.1% (95% CI 0.6–2.0%; Table 1). Seven of the acutely infected patients (64%) were women, and the median age was 34 years (Table 1). All of the participants with acute HIV infection had HIV RNA >750 000 copies/mL (range 750 000–22 200 000 copies/mL). One patient had two concordant negative rapid HIV tests (in the parallel testing period), a positive EIA and insufficient specimen available for a WB. However, her quantitative Avelestat (AZD9668) HIV RNA was 22 200 000 copies/mL, compatible with acute infection; she was included among the 11 acutely infected patients based on the unanimous consensus of five clinical HIV experts who were consulted to assist with classifying this case. Two of the 11 acutely infected cases (one male and one female) had discordant rapid HIV tests; the other nine had negative rapid HIV tests. Of 976 patients who had a negative rapid test and underwent qualitative RNA screening, 954 (98%) were confirmed to be HIV negative by qualitative HIV RNA testing (Fig. 1; left side). Twenty-two patients with negative rapid HIV tests had positive qualitative HIV RNA testing.